Stockreport

Dynavax doses first subject in Phase I/II shingles vaccine trial [Yahoo! Finance]

Dynavax Technologies Corporation  (DVAX) 
Last dynavax technologies corporation earnings: 3/11 04:10 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.dynavax.com
PDF The active-controlled, randomised, dose escalation, multi-centre trial is anticipated to enrol around 440 healthy adults aged 50 to 69 years across multiple sites in Au [Read more]